Latest Articles
New endometriosis pill on the NHS could benefit more than 1,000 women a year - Wired-Gov
New endometriosis pill on the NHS could benefit more than 1,000 women a year Wired-Gov
Published: May 2, 2025, 8:14 a.m.
NICE Backs Oral Treatment Linzagolix for Endometriosis - Medscape
NICE Backs Oral Treatment Linzagolix for Endometriosis Medscape
Published: May 2, 2025, 7:15 a.m.
Insights into endometriosis symptom trajectories and assessment of surgical intervention outcomes using longitudinal actigraphy - Nature
Insights into endometriosis symptom trajectories and assessment of surgical intervention outcomes using longitudinal actigraphy Nature
Published: May 2, 2025, 5:38 a.m.
Women with endometriosis at higher risk of immune conditions, study finds - Oxford Mail
Women with endometriosis at higher risk of immune conditions, study finds Oxford Mail
Published: May 2, 2025, 4 a.m.
Women with endometriosis at higher risk of immune conditions, study finds - This Is Oxfordshire
Women with endometriosis at higher risk of immune conditions, study finds This Is Oxfordshire
Published: May 2, 2025, 4 a.m.
Endometriosis Raises Risk of Premature Menopause, Study Finds - Medical Dialogues
Endometriosis Raises Risk of Premature Menopause, Study Finds Medical Dialogues
Published: May 2, 2025, 2:45 a.m.
Endometriosis linked to premature and early menopause - NZ Doctor
Endometriosis linked to premature and early menopause NZ Doctor
Published: May 2, 2025, 1:09 a.m.
Little-known Endometriosis symptoms as new pill approved on NHS - Daily Express
Little-known Endometriosis symptoms as new pill approved on NHS Daily Express
Published: May 2, 2025, 12:30 a.m.
Endometriosis signs and symptoms as new pill approved for painful condition - Surrey Live
Endometriosis signs and symptoms as new pill approved for painful condition Surrey Live
Published: May 2, 2025, 12:22 a.m.
Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial.
To evaluate the safety and pharmacokinetics/pharmacodynamics of AMY109, an anti-interleukin-8 recycling antibody in a first-in-human phase 1 trial in healthy volunteers (HVs) and patients with endometriosis.
Published: May 2, 2025, midnight
Link copied to clipboard!